Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLOTRIMAZOLE

All products: general benefit

Other products in the same Health Canada class (G01A) — coverage varies; not interchangeable

  • Nystatin (Mycostatin): general benefit, Not a benefit
  • Terconazole (Terazol 7): general benefit, Not a benefit

Canesten 3 Cream · DIN 02150905 · 20mg/g · Vag Cr-App

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Canesten 3 Cream · DIN 02150905 Manufacturer: Bayer Inc., Consumer Care Division; listing date 1996-10-01 Health Canada: Marketed since 2018-11-09 · brand CANESTEN 3 DAY INTERNAL CREAM · ATC G01AF02 CLOTRIMAZOLE · form Cream · route Vaginal · ingredients CLOTRIMAZOLE 2 %/W/W · company Bayer inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Ministry pays: $0.3624 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19484 · Verify on the e-Formulary ↗ (DIN 02150905)

Source record
DIN 02150905: Canesten 3 Cream Raw flags: sec3=Y Item: 840408027; group id 818; item number 2000; lccId None; manufacturer id BAY Source form: Vag Cr-App; strength: 20mg/g Recorded listing: General benefit Source prices (unrounded): $0.4424; ministry $0.3624 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02150905 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19484
Interchangeable products
Clotrimaderm Vaginal Cream · DIN 00812374 · $0.3624
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): KETOCONAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

FLUCONAZOLE

· 8 products · Limited Use, codes 235 · strengths: 150mg · Cap

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Clotrimaderm Vaginal 6 (clotrimazole) is indicated for the 6-day treatment of vaginal candidiasis. Clotrimaderm Vaginal 3 (clotrimazole) is indicated for the 3-day treatment of vaginal candidiasis. 1.1 Pediatrics Pediatrics (>12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Clotrimazole in pediatric patients (>12 years of age) has been established. Therefore, Health Canada has authorized an indication for pediatric (>12 years of age) use. https://pdf.hres.ca/dpd_pm/00081078.PDF PM date: July 16, 2025 Source product: CLOTRIMADERM VAGINAL 6; DIN 00812366; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.